This analysis used data from 3 randomized , double-blind , placebo-controlled phase III trials of perampanel as an add-on therapy in patients with epilepsy who were experiencing refractory partial seizures : studies 304 ( ClinicalTrials.gov identifier NCT00699972 ) , 305 ( NCT00699582 ) , and 306 ( NCT00700310 ) .